AZD7325 Multiple Ascending Dose Study

Inclusion Criteria: * Female subjects must be of non-child bearing potential. Exclusion Criteria: * Clinically significant illness within 2 weeks before the study start. * Enrollment in another concurrent investigational study or intake of an investigational drug within 30 days or intake of an investigational drug within a period of 5 half lives of that drug prior to the screening visit * Blood loss in excess of 200 mL within 30 days of Day -2, in excess of 400 mL within 90 days of Day -2, or in excess of 1200 mL within 1 year of Day -2 * Clinically relevant abnormalities in physical examinations, vital signs, ECG, clinical chemistry, hematology or urinalysis